Clinical trials: Glioma, Malignant
Recurrent Glioblastoma, Glioblastoma
CUE-102 in Recurrent Glioblastoma
The goal of this study is to evaluate the safety of the experimental drug, CUE-102, and establish the recommended dose of CUE-102 for participants with Recurrent Glioblastoma (GBM).
- Conditions
- Recurrent Glioblastoma, Glioblastoma, Glioma, Malignant
- Trial name
- NCT06917885
- Testing
- CUE-102
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- David Reardon, MD
Recurrent Childhood Anaplastic Astrocytoma, Recurrent Childhood Brain Stem Glioma
Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors
This phase I/II trial studies lapatinib to see how well it works in treating young patients with recurrent or refractory central nervous system (CNS) tumors.
- Conditions
- Recurrent Childhood Anaplastic Astrocytoma, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Ependymoma, Recurrent Childhood Giant Cell Glioblastoma
- Trial name
- NCT00095940
- Testing
- lapatinib ditosylate, therapeutic conventional surgery, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent High-Grade Gliomas, Progressive Low-Grade Gliomas
ZD6474 to Treat Advanced Brain Cancer in Patients
Background: In vivo experiments have documented the ability of ZD6474 to inhibit tumor growth in various preclinical tumor models.
- Conditions
- Recurrent High-Grade Gliomas, Progressive Low-Grade Gliomas, Malignant Gliomas
- Trial name
- NCT00272350
- Testing
- Steroids, ZD6474
- Where
- United States
- Volunteers
- 83 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Solid Tumors, Head and Neck Cancer
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
Phase 1a/1b does-escalation study of cabiralizumab alone and with nivolumab in advanced solid tumors.
- Conditions
- Advanced Solid Tumors, Head and Neck Cancer, Pancreatic Cancer, Ovarian Cancer
- Trial name
- FPA008-003 (NCT02526017)
- Testing
- Cabiralizumab, Nivolumab
- Where
- 39 sites in United States
- Volunteers
- 313 people
- Sponsor
- Five Prime Therapeutics, Inc.
Malignant Glioma
Bevacizumab Plus Irinotecan Plus Carboplatin for Recurrent Malignant Glioma (MG)
The purpose of this study is to determine whether Bevacizumab, CPT-11 and Carboplatin in combination are effective in the treatment of recurrent malignant glioma.
- Trial name
- NCT00953121
- Testing
- bevacizumab and CPT-11 and Carboplatin
- Where
- United States
- Volunteers
- 104 people
- Sponsor
- Annick Desjardins
Malignant Glioma
Nuvigil or Placebo in Newly Diagnosed Malignant Glioma
The purpose of this study is to determine if Nuvigil® improves fatigue experienced by people receiving external beam radiation therapy for the treatment of malignant gliomas.
- Trial name
- NCT01400958
- Testing
- Nuvigil®
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Medulloblastoma, Central Nervous System Tumor, Pediatric
Genetic and Molecular Risk Profiles of Pediatric Malignant Brain Tumors in China
Primary malignant central nervous system (CNS) tumors are the second most common childhood malignancies. Amongst, medulloblastomas are the most common malignant brain tumor of childhood and occur primarily in the cerebellum.
- Conditions
- Medulloblastoma, Central Nervous System Tumor, Pediatric, Ependymoma, Germ Cell Tumor
- Trial name
- GRIPP (NCT05672043)
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Beijing Tiantan Hospital
Brain Tumor, Glioblastoma
Suberoylanilide Hydroxamic Acid (SAHA), Bevacizumab, Daily Temozolomide for Recurrent Malignant Gliomas
This is a Phase I/II open-label, single-arm study among recurrent malignant glioma patients. Patients will be treated with Vorinostat in combination with Bevacizumab (BV) (10 mg/kg) and Temozolomide (T) (50 mg/m2/day) BV is…
- Trial name
- NCT00939991
- Testing
- Vorinostst/Bevacizumab/Temozolomide
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Katy Peters
Central Nervous System Lymphoma, Malignant Glioma
Ferumoxytol in Improving MR Imaging in Patients With High-Grade Brain Tumors or Cerebral Metastases
This clinical trial studies magnetic resonance imaging (MRI) using a contrast imaging agent ferumoxytol (ferumoxytol non-stoichiometric magnetite) in improving viewing tumors in patients with high-grade brain tumors or cancer…
- Conditions
- Central Nervous System Lymphoma, Malignant Glioma, Metastatic Malignant Neoplasm in the Brain
- Trial name
- NCT00103038
- Testing
- 3 Tesla Magnetic Resonance Imaging, Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging
- Where
- United States
- Volunteers
- 155 people
- Sponsor
- OHSU Knight Cancer Institute
Cancer, Solid Tumor
Oral AMXT 1501 Dicaprate in Combination With IV DFMO
A Phase 1B/2A study will be conducted to establish safety and dose level of AMXT 1501 dicaprate in combination with IV DFMO, in cancer patients.
- Conditions
- Cancer, Solid Tumor, Solid Carcinoma, Advanced Cancer
- Trial name
- NCT05500508
- Testing
- AMXT1501, DFMO
- Where
- 7 sites in United States, Australia
- Volunteers
- 15 people
- Sponsor
- Aminex Therapeutics, Inc.
High Grade Glioma
Minimized Time to Beam in Patients With High Grade Gliomas
A Pilot Study Evaluating Minimized Time to Beam Hypofractionated IMRT with PET Assisted Target Definition in Patients with High Grade Gliomas The aim of this pilot project is to explore the feasibility of combining a simple…
- Trial name
- NCT00469534
- Testing
- IMRT
- Sponsor
- Alberta Health services
Glioma, Anaplastic Astrocytoma
Dendritic Cell Vaccine for Patients With Brain Tumors
The main purpose of this study is to evaluate the most effective immunotherapy vaccine components in patients with malignant glioma.
- Conditions
- Glioma, Anaplastic Astrocytoma, Anaplastic Astro-oligodendroglioma, Glioblastoma
- Trial name
- NCT01204684
- Testing
- autologous tumor lysate-pulsed DC vaccination, Tumor lysate-pulsed DC vaccination+0.2% resiquimod, Tumor-lysate pulsed DC vaccination +adjuvant polyICLC
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Meningioma, Glioblastoma
Pilot Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Intracranial Lesions During Neurosurgical Procedures
This pilot clinical study evaluates the safety and imaging performance of panitumumab-IRDye800 (pan800), a fluorescent, EGFR-targeted imaging agent - in patients undergoing neurosurgical resection of intracranial lesions.
- Conditions
- Meningioma, Glioblastoma, Acoustic Neuroma, Brain Cancer
- Trial name
- NCT07493447
- Testing
- Panitumumab-IRDye800
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Eben Rosenthal
Malignant Glioma, Anxiety
Psychological Intervention For Brain Tumor Caregivers
This study is testing a supportive psychosocial intervention for caregivers of people who have malignant brain tumors such as gliomas or other high-grade primary brain tumors.
- Conditions
- Malignant Glioma, Anxiety, Caregiver Burden, Malignant Brain Tumor
- Trial name
- NCT04109209
- Testing
- Psychosocial Intervention Group, Usual Care Group
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Malignant Glioma, Ependymoma
Optune for Children With High-Grade Glioma or Ependymoma, and Optune With Radiation Therapy for Children With DIPG
This is a multicenter trial of the Optune device to examine the feasibility and to describe the device-related toxicity in children with supratentorial high grade glioma (HGG) or ependymoma (Stratum 1) and to examine the…
- Conditions
- Malignant Glioma, Ependymoma, Diffuse Intrinsic Pontine Glioma
- Trial name
- NCT03033992
- Testing
- Optune System (NovoTTF-200A System, Tumor Treating Fields, TTFields), Concurrent Optune and RT followed by Optune System alone
- Where
- 11 sites in United States
- Volunteers
- 80 people
- Sponsor
- Children's Oncology Group
Recurrent Ependymoma, Recurrent Ewing Sarcoma
Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)
This phase II Pediatric MATCH trial studies how well ivosidenib works in treating patients with solid tumors, including central nervous system tumors, lymphomas and histiocytic disorders that have not responded to (refractory) or…
- Conditions
- Recurrent Ependymoma, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma, Recurrent Langerhans Cell Histiocytosis
- Trial name
- NCT04195555
- Testing
- Ivosidenib
- Where
- 174 sites in United States, Australia and 1 more
- Volunteers
- 3 people
- Sponsor
- National Cancer Institute (NCI)
Glioblastoma, Brain Metastases
PET/CT Imaging of Malignant Brain Tumors With 124I-NM404
The purpose of this study is to evaluate diagnostic imaging techniques using 124I-NM404 PET/CT in humans with brain metastases and GBMs.
- Trial name
- NCT01516905
- Testing
- NM404
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of Wisconsin, Madison
Advanced Solid Tumor
Safety, Tolerability, PK/PD & Preliminary Efficacy of SKL27969 in Advanced Solid Tumors Patients
Primary Objective of Part 1 (Dose Escalation Phase): Evaluate the safety and tolerability of SKL27969, and determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of SKL27969 Primary Objective of Part 2…
- Trial name
- NCT05388435
- Testing
- SKL27969
- Where
- 4 sites in United States
- Volunteers
- 15 people
- Sponsor
- SK Life Science, Inc.
Malignant Glioma
Study of NPC-08 is to Treat for Newly-Diagnosed Malignant Glioma and Recurrent Glioblastoma Multiforme
The purpose of this study is to evaluate whether NPC-08 is safety and efficacy in the treatment of newly-diagnosed malignant glioma and recurrent glioblastoma multiforme.
- Trial name
- NCT00919737
- Testing
- NPC-08
- Where
- Japan
- Volunteers
- 24 people
- Sponsor
- Nobelpharma
Glioma, Glioblastoma
Phase II Elderly/Frail Pts With Newly Diagnosed or Recurrent Malignant Glioma Treated With Cesium-131 GammaTile®
This is a phase 2, open-label clinical trial determining feasibility, safety, and tolerability of GammaTile® in elderly or frail subjects with newly diagnosed or recurrent malignant gliomas.
- Conditions
- Glioma, Glioblastoma, GBM, Glioma, Malignant
- Trial name
- ENDURANCE (NCT07821112)
- Testing
- GammaTile®
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of California, Irvine
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.